Collagen neoepitope antibody
AssigneeShionogi & Co., Ltd.
InventorsYoshito Numata, Akira Yamauchi, Junji Onoda, Shoji Yamane, Tomoko Maeda
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel monoclonal antibody that is specific for a C-terminal neoepitope of a collagen fragment and has substantially equal binding affinity whether proline contained in the neoepitope is in a non-hydroxylated form or in a hydroxylated form, and an immunoassay, a measurement method, a kit and the like using the antibody. The antibody allows for quantification of a collagen fragment generated by digestion of a biological sample with a collagenase present in the sample, regardless of the presence or absence of a hydroxylated form of proline in the neoepitope.
Claims15
A monoclonal antibody specifically binding to a collagen neoepitope fragment at positions 962 to 975 of the amino acid sequence shown in SEQ ID NO:
- 20, wherein the binding affinity is substantially the same whether proline contained in said epitope is in a non-hydroxylated form or in a hydroxylated form.
A monoclonal antibody having:
- a) in a complementarity-determining region, a heavy chain variable region containing the following amino acid sequences:
- KYGIN (SEQ ID NO:
- 5), WINTYSGMTT YADDFKG (SEQ ID NO:
- 6), and SLGYDYGGFAY (SEQ ID NO:
- 7);
- and
- b) in a complementarity-determining region, a light chain variable region containing the following amino acid sequences:
- RSGQTLVHDNENTYFH (SEQ ID NO:
- 8), KISNRFS (SEQ ID NO:
- 9), and SQNTHVPFT (SEQ ID NO:
- 10).
A monoclonal antibody having:
- a) a heavy chain variable region containing the amino acid sequence of SEQ ID NO:
- 3;
- and
- b) a light chain variable region containing the amino acid sequence of SEQ ID NO:
- 4.
(canceled)
Dependencies are inferred from the claim text.